Premium Insights - page 2 | BiopharmaTrend

The €25B vs €219B Problem: Europe's Plan to Fix Biotech

Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking. Between 2015 and mid-2025, EU biotech startups attracted €25B …

Continue ›››

Cancer as a Data Problem: What AI Is Doing in Oncology

We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to handle multi-step oncology research tasks. Cancer …

Continue ›››

Five Genomics Watchpoints for 2026

Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one end-to-end pipeline. The beginning of this year is already offering …

Continue ›››

New-Modality Drugs Behind Today’s Big Headlines

How advanced therapeutics are solving “undruggable” biology and creating industry’s most valuable assets. A lot has been happening lately across biopharma spanning massive deals and landmark approvals. Madrigal Pharmaceuticals has …

Continue ›››

Five Women Shaping the AI–Life Science Stack

February 11 marks the UN-designated International Day of Women and Girls in Science, established by the General Assembly in December 2015 to recognize the contributions of women in scientific fields …

Continue ›››

Big Pharma’s China Deal Wave & 12 Companies on Our Radar

A snap look at some of the deal dynamics and company platforms pulling global pharma toward China. In late January, AstraZeneca announced a $15B investment in China through 2030, expanding …

Continue ›››

How 2026 Started: First-Weeks Readout on AI, Pharma, & Policy

Early-year overview spanning virtual cell modeling, AI workflow plumbing in R&D and healthcare, obesity-driven capital and licensing, patent-cliff positioning, and FDA/EU policy signals. The year opened hot, with the first …

Continue ›››

2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech restoration, and early clinical proof points. As we step …

Continue ›››

Aging, AI, and the Uneven Road to Longevity Medicine

Echoing notes from ARDD2025, we briefly overview geroscience, its fusion with AI, what companies pursue in this field and limitations on the way of longevity medicine. А couple of weeks …

Continue ›››

Generative Diffusion in Molecular Design

A quick field guide to diffusion-based generators in molecular design—how they work, where they complement transformers, and who is deploying them today. Last week, Californian drug discovery startup Terray Therapeutics …

Continue ›››

Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape

Drawing on new discussions from ARDD2025 in Copenhagen, the focus turns to how GLP-1s, IPF, and the gut microbiome are steering aging drug development Over the past decade, aging research …

Continue ›››

Protein Language Models: Builders & Pharma Deals

Chan Zuckerberg Initiative, the group behind the recent virtual cell efforts, has “acqui-hired” EvolutionaryScale’s ~50-person team, folding it into the expanding Biohub network. The move comes as CZI pivots to …

Continue ›››